Vir Biotechnology (VIR) Share-based Compensation (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Share-based Compensation data on file, last reported at $12.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 14.03% year-over-year to $12.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (down 92.21% YoY), and the FY2025 full-year result was $7.3 million, down 90.66% from the prior year.
• Share-based Compensation grew to $12.1 million in Q1 2026, from -$30.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $62.6 million in Q3 2024 to a low of -$83.0 million in Q4 2023.
• A 5-year average of $11.8 million and a median of $24.8 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation tumbled 433.98% in 2023 and soared 132.39% in 2024, its largest moves.
• Tracing VIR's Share-based Compensation over 5 years: stood at $24.9 million in 2022, then plunged by 433.98% to -$83.0 million in 2023, then soared by 119.08% to $15.8 million in 2024, then tumbled by 292.77% to -$30.5 million in 2025, then soared by 139.58% to $12.1 million in 2026.
• Business Quant data shows VIR's Share-based Compensation at $12.1 million in Q1 2026, -$30.5 million in Q4 2025, and $30.3 million in Q3 2025.